Interleukin-2-inducible T-cell kinase (ITK) inhibitor (IC50 values are 0.1, 0.4 and 5 μM for ITK, BTK and ETK, respectively). Inhibits growth of cancer cells expressing ITK, including MOLT-4 and Jurkat cells in vitro. Induces apoptosis in Jurkat cells. Inhibits MOLT-4 xenograft tumor growth in mice.
Guo et al (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol.Pharmacol. 82 938 PMID:22899868
















